Protocol Ledger

NCT04223596 · Phase II · ACTIVE NOT RECRUITING

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Interventional Phase II clinical trial protocol NCT04223596 sponsored by Fundación GECP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-04 Enrollment: 33 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04223596
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04223596
Protocol FieldVerified Registry Value
NCT IdentifierNCT04223596
Consolidated Lead SponsorFundación GECP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment33 participants (ACTUAL)
Registered Start Date2020-05-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04223596
Hospital Research SiteLocationSite Profile
Hospital de La Santa Creu I Sant PauBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitario Fundación Jiménez DíazMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI